Sachdev Amit 4
4 · VERTEX PHARMACEUTICALS INC / MA · Filed Feb 23, 2026
Research Summary
AI-generated summary of this filing
Vertex (VRTX) EVP Amit Sachdev Exercises Options and Sells Shares
What Happened
- Amit Sachdev, EVP, Chief Patient & External Affairs Officer at Vertex, exercised two option grants on 2026-02-19 to acquire 48,505 shares (23,479 at $155.57 = $3,652,628; 25,026 at $187.53 = $4,693,126; total cost ≈ $8,345,754).
- The filing also reports multiple open‑market sales the same day totaling 58,613 shares sold for aggregate proceeds of $27,479,582 (individual sale prices ranged roughly $463.44–$472.03; weighted averages noted per line).
- Two derivative lines show the option instruments were converted/terminated (reported as disposed at $0) in connection with the exercises. This pattern—exercise followed by same‑day sales—is effectively a cashless exercise and sale of the acquired shares.
Key Details
- Transaction date: 2026-02-19; Form 4 filed 2026-02-23 (within the standard reporting window).
- Exercises: 23,479 @ $155.57 ($3,652,628) and 25,026 @ $187.53 ($4,693,126).
- Open‑market sales: 58,613 shares at prices from ~$463.44 to $472.03; total proceeds ≈ $27,479,582. One line’s weighted average noted as $471.43 (range $471.10–$472.03).
- Shares owned after transaction: not specified in the filing.
- Footnotes: trades were made under a company‑approved Rule 10b5‑1 plan entered 11/18/2025 (F1); options were fully vested (F11). The filer commits to providing a per‑price breakdown on request (F3).
Context
- Because the exercises and sales occurred the same day and the derivative lines report $0 disposals, this is effectively a cashless exercise (exercise of options followed by sale of shares). Such activity is commonly driven by option exercise/tax-liability management rather than an expressed change in view on the company.
- Trades were executed under a pre‑arranged 10b5‑1 trading plan, which typically means the sales were scheduled in advance. This is routine insider selling and not, by itself, evidence of new information about company fundamentals.
Insider Transaction Report
Form 4
Sachdev Amit
EVP Chief Patient & Ext Af Off
Transactions
- Exercise/Conversion
Common Stock
2026-02-19$155.57/sh+23,479$3,652,628→ 92,521 total - Exercise/Conversion
Common Stock
2026-02-19$187.53/sh+25,026$4,693,126→ 117,547 total - Sale
Common Stock
[F1][F2][F3]2026-02-19$463.91/sh−920$426,797→ 116,627 total - Sale
Common Stock
[F1][F3][F4]2026-02-19$465.05/sh−2,730$1,269,587→ 113,897 total - Sale
Common Stock
[F1][F3][F5]2026-02-19$465.80/sh−1,848$860,798→ 112,049 total - Sale
Common Stock
[F1][F3][F6]2026-02-19$467.75/sh−10,263$4,800,518→ 101,786 total - Sale
Common Stock
[F1][F3][F7]2026-02-19$468.57/sh−19,662$9,213,023→ 82,124 total - Sale
Common Stock
[F1][F3][F8]2026-02-19$469.61/sh−7,241$3,400,446→ 74,883 total - Sale
Common Stock
[F1][F3][F9]2026-02-19$470.54/sh−11,712$5,510,964→ 63,171 total - Sale
Common Stock
[F1][F3][F10]2026-02-19$471.43/sh−4,237$1,997,449→ 58,934 total - Exercise/Conversion
Stock Option (Right to Buy)
[F11]2026-02-19−23,479→ 0 totalExercise: $155.57Exp: 2028-02-05→ Common Stock (23,479 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
[F11]2026-02-19−25,026→ 0 totalExercise: $187.53Exp: 2029-02-05→ Common Stock (25,026 underlying)
Holdings
- 882(indirect: By 401(k))
Common Stock
- 9,301(indirect: By Trust)
Common Stock
Footnotes (11)
- [F1]Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1, which was entered into on 11/18/2025.
- [F10]Open market sales reported on this line occurred at a weighted average price of $471.43 (range $471.10 to $472.03).
- [F11]Fully vested.
- [F2]Open market sales reported on this line occurred at a weighted average price of $463.91 (range $463.44 to $464.28).
- [F3]Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- [F4]Open market sales reported on this line occurred at a weighted average price of $465.05 (range $464.48 to $465.46).
- [F5]Open market sales reported on this line occurred at a weighted average price of $465.80 (range $465.54 to $466.49).
- [F6]Open market sales reported on this line occurred at a weighted average price of $467.75 (range $467.09 to $468.05).
- [F7]Open market sales reported on this line occurred at a weighted average price of $468.57 (range $468.10 to $469.09).
- [F8]Open market sales reported on this line occurred at a weighted average price of $469.61 (range $469.10 to $470.05).
- [F9]Open market sales reported on this line occurred at a weighted average price of $470.54 (range $470.10 to $471.08).
Signature
/s/ Christiana Stevenson, Attorney-in-Fact|2026-02-23